Omeros Corporation
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Last updated:
Abstract:
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Status:
Application
Type:
Utility
Filling date:
18 Nov 2021
Issue date:
3 Mar 2022